Pharsight

Pomalyst patents expiration

POMALYST's oppositions filed in EPO
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8828427 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Jun, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673939 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(4 months ago)

US8735428 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(4 months ago)

US8735428

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(a month from now)

US8673939

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(a month from now)

US8198262 CELGENE Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Jun, 2025

(1 year, 8 months from now)

US8198262

(Pediatric)

CELGENE Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Dec, 2025

(2 years from now)

US9993467 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(6 years from now)

US10555939 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(6 years from now)

US9993467

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(7 years from now)

US10555939

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(7 years from now)

US8828427

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Dec, 2031

(8 years from now)

Pomalyst is owned by Celgene.

Pomalyst contains Pomalidomide.

Pomalyst has a total of 12 drug patents out of which 2 drug patents have expired.

Expired drug patents of Pomalyst are:

  • US8673939
  • US8735428

Pomalyst was authorised for market use on 08 February, 2013.

Pomalyst is available in capsule;oral dosage forms.

Pomalyst can be used as use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma, use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy.

The generics of Pomalyst are possible to be released after 21 December, 2031.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Nov 20, 2023
Orphan Drug Exclusivity (ODE) May 14, 2027
Pediatric Exclusivity (PED) Nov 14, 2027

Drugs and Companies using POMALIDOMIDE ingredient

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a pro...

Dosage: CAPSULE;ORAL

How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage

POMALYST family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic